Marrying your cousin has long been considered taboo, but new research says that procreating with your cousins may not be as risky as previously thought. Popular Science's Eleanor Cummins breaks down the findings.
Eleanor Cummins, Editorial Assistant at Popular Science, breaks down the findings. Columbia University data scientist Yaniv Erlich studied a family tree of 13 million people to see how marrying various relatives impacts the risk of genetic birth defects. He found that one set of first cousins having children doesn't necessarily pose a high risk of having children with birth defects, but if the trend continues beyond one generation, then the risk increases exponentially.
The sophisticated rocket sent a payload that included 24 satellites, a new, solar-powered space sail, and the ashes of 152 people, into space with its side boosters successfully returning to Earth unscathed.
That next step for meat alternatives will apparently include fish as companies like Wild Type, BlueNalu, and Finless Foods wager that, in the age of plant-based burgers, there’s room for seafood grown in the lab.
These are the headlines you Need 2 Know for Wednesday, June 19, 2019.
Elon Musk may be going to Vegas. The Las Vegas Convention and Visitors Authority has recommended that The Boring Company be chosen to construct a "people mover" below the expanding convention center.
Cannabis, hemp, reefer, marijuana, dope, pot, grass ー no matter what term you choose, they all refer to the same plant: cannabis sativa. It’s a common misconception that cannabis sativa exclusively means that particular strain of weed that makes you creative and focused (as opposed to indica, which promotes relaxation)ー but it’s actually the scientific name of the single plant that yields marijuana, CBD, and hemp, among other products.
These are the headlines you Need 2 Know for Tuesday, Feb. 19, 2019.
Canopy Growth CEO Bruce Linton won't guarantee investors dividends. What he will promise is a stake in global cannabis domination. "If people want a dividend, we are probably not the right stock. If they want some entity aimed at dominating a global opportunity that started in Canada, we are probably your best bet," Linton told Cheddar on Friday, one day after the company reported a massive spike in third-quarter revenue.
These are the headlines you Need 2 Know for Friday, Feb, 15, 2019.
It's a big week in cannabis earnings ー Aurora Cannabis reported Monday and Canopy Growth will report Thursday ー but Paul Rosen, CEO of cannabis private equity firm Tidal Royalty, said he's noticing a concerning trend."All the companies are facing gross margin compression because there are excise taxes, there's a massive marketing spend as we go to recreational cannabis, and there's also increased packaging costs. So I think you're going to see a trend line here, which is revenue and capacity going up, but gross margin is going down," Rosen told Cheddar Wednesday.
Opiant Pharmaceuticals, the developer of opioid antidote NARCAN, is in the process of developing a version of its lifesaving drug for cannabanoid overdoses, the company's CEO told Cheddar in an interview on Wednesday.
